Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications

Shen Chieh Chang, Winston W. Shen

研究成果: 雜誌貢獻回顧型文獻同行評審

3 引文 斯高帕斯(Scopus)

摘要

The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.
原文英語
頁(從 - 到)210-216
頁數7
期刊Journal of Experimental and Clinical Medicine(Taiwan)
5
發行號6
DOIs
出版狀態已發佈 - 十二月 2013

ASJC Scopus subject areas

  • 醫藥 (全部)

指紋

深入研究「Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications」主題。共同形成了獨特的指紋。

引用此